ERK1 (MAPK3) — Extracellular Signal-Regulated Kinase 1

ERK1 (MAPK3) — Extracellular Signal-Regulated Kinase 1

Overview

MAPK3 (Mitogen-Activated Protein Kinase 3), commonly known as ERK1 (Extracellular Signal-Regulated Kinase 1) or p44 MAPK, is a serine/threonine kinase that plays critical roles in cellular signal transduction, neuronal function, and synaptic plasticity. As a key component of the MAPK/ERK signaling pathway, ERK1 transduces extracellular signals from growth factors, neurotransmitters, and cellular stress into intracellular responses that regulate gene expression, cell survival, and neuronal plasticity.

ERK1 has emerged as a significant player in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. Dysregulation of ERK1 signaling contributes to amyloid-beta (Aβ) toxicity, tau hyperphosphorylation, dopaminergic neuron degeneration, and neuroinflammation. The pathway represents both a therapeutic target and a potential biomarker for neurodegeneration[@kim2022][@maqbool2023].

ERK1 (MAPK3) — Extracellular Signal-Regulated Kinase 1

Overview

MAPK3 (Mitogen-Activated Protein Kinase 3), commonly known as ERK1 (Extracellular Signal-Regulated Kinase 1) or p44 MAPK, is a serine/threonine kinase that plays critical roles in cellular signal transduction, neuronal function, and synaptic plasticity. As a key component of the MAPK/ERK signaling pathway, ERK1 transduces extracellular signals from growth factors, neurotransmitters, and cellular stress into intracellular responses that regulate gene expression, cell survival, and neuronal plasticity.

ERK1 has emerged as a significant player in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. Dysregulation of ERK1 signaling contributes to amyloid-beta (Aβ) toxicity, tau hyperphosphorylation, dopaminergic neuron degeneration, and neuroinflammation. The pathway represents both a therapeutic target and a potential biomarker for neurodegeneration[@kim2022][@maqbool2023].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Extracellular Signal-Regulated Kinase 1 (ERK1/MAPK3)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>MAPK3</td></tr>
<tr><td><strong>Protein Name</strong></td><td>ERK1, p44 MAPK</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16p11.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5595](https://www.ncbi.nlm.nih.gov/gene/5595)</td></tr>
<tr><td><strong>OMIM</strong></td><td>601795</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000102882</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P27361](https://www.uniprot.org/uniprot/P27361)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>MAPK family, ERK subfamily</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, nucleus</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>AD, PD, ALS, Stroke, Brain Injury</td></tr>
</table>
</div>

Gene and Protein Structure

Genomic Organization

The MAPK3 gene is located on chromosome 16p11.2 and spans approximately 9.4 kb of genomic DNA. The gene consists of 10 exons that encode a protein of 367 amino acids with a molecular weight of approximately 44 kDa. The gene promoter contains binding sites for multiple transcription factors including Sp1, AP-1, and CREB, allowing for complex regulation in response to various cellular signals[@roskoski2024].

Protein Domain Architecture

ERK1 contains several functional domains:

The kinase domain adopts a typical bilobal structure with:

• N-lobe: ATP-binding pocket with glycine-rich loop
• C-lobe: Catalytic site and substrate recognition surface

MAPK/ERK Signaling Pathway

Upstream Activation

The MAPK/ERK cascade is activated by diverse extracellular stimuli:

Cascade Components

| Level | Kinase | Function |
|-------|--------|----------|
| MAPKKK | RAF (A/B/C) | Activates MEK |
| MAPKK | MEK1/2 | Phosphorylates ERK |
| MAPK | ERK1/2 | Effector kinases |
| MAPKAPK | RSK, MSK, MNK | Secondary effectors |

Regulation Mechanisms

ERK1 activity is tightly regulated through:

Functions in the Nervous System

Synaptic Plasticity

ERK1 plays a critical role in synaptic plasticity, the cellular basis of learning and memory[@huang2020]:

• Long-term potentiation (LTP): ERK1 is activated during LTP and is required for LTP maintenance
• Long-term depression (LTD): ERK1 signaling contributes to AMPA receptor internalization
• Dendritic spine morphogenesis: ERK1 regulates actin cytoskeleton dynamics
• Local protein synthesis: ERK1 phosphorylates translational regulators (eCREB, eIF4E)

Neuronal Development

During brain development, ERK1 signaling controls:

• Neurogenesis: Regulates progenitor cell proliferation and differentiation
• Migration: Controls neuronal migration via cytoskeletal remodeling
• Axonal guidance: Mediates growth cone responses to guidance cues
• Synaptogenesis: Orchestrates presynaptic and postsynaptic differentiation

Gene Expression Regulation

ERK1 translocates to the nucleus where it phosphorylates:

• Transcription factors: CREB, Elk-1, c-Fos, c-Myc
• Chromatin regulators: Histone H3, HDAC
• RNA processing: Alternative splicing factors

Brain Expression and Localization

Regional Distribution

ERK1 is widely expressed throughout the brain with highest levels in regions associated with cognitive function[@kim2022]:

| Brain Region | Expression Level | Functional Significance |
|-------------|-----------------|----------------------|
| [Hippocampus](/brain-regions/hippocampus) | Very High | CA1-CA3, dentate gyrus — memory processing |
| Cerebral [Cortex](/brain-regions/cortex) | High | Layer 2/3, 5 pyramidal neurons — cognition |
| Basal Forebrain | High | Cholinergic neurons — attention |
| [Amygdala](/brain-regions/amygdala) | Moderate-High | Emotional memory |
| Cerebellum | Moderate | Purkinje cells — motor learning |
| [Striatum](/brain-regions/striatum) | Moderate | Medium spiny neurons — movement |

Cell Type Expression

• Excitatory glutamatergic neurons: High expression — synaptic plasticity
• Inhibitory GABAergic neurons: Moderate expression — network regulation
• [Astrocytes](/entities/astrocytes): Low-Moderate — glia-neuron signaling
• [Microglia](/cell-types/microglia-neuroinflammation): Inducible — activation-dependent
• Oligodendrocytes: Moderate — myelination regulation

Subcellular Localization

ERK1 exhibits dynamic subcellular distribution:

• Dendritic shafts: Associates with dendritic spines
• Synaptic vesicles: Regulates presynaptic function
• Nucleus: Controls gene expression programs
• Mitochondria: Influences metabolic function

Role in Alzheimer's Disease

Amyloid-Beta Pathogenesis

ERK1 is deeply involved in Aβ-induced neuronal dysfunction[@maqbool2023][@choi2019]:

ERK1 phosphorylates tau at disease-relevant sites:

• Ser262 (multiple repeat isoforms)
• Ser396 (PHF-tau epitope)
• Ser404 (AD-tau epitope)

Neuroinflammation

ERK1 mediates neuroinflammatory responses in AD[@xu2021]:

• Microglial activation: Aβ stimulates ERK1 in microglia
• Cytokine production: ERK1 regulates IL-1β, TNF-α, IL-6
• Neuronal stress: Inflammatory ERK1 signaling exacerbates toxicity

Therapeutic Implications

Targeting ERK1 in AD:

| Strategy | Approach | Status |
|----------|----------|--------|
| MEK inhibitors | Block ERK activation | Preclinical |
| Tau kinase inhibitors | Prevent tau phosphorylation | Research |
| Anti-inflammatory | Reduce ERK-mediated inflammation | Clinical trials |
| Neurotrophic factors | Activate protective ERK signaling | Research |

Role in Parkinson's Disease

Dopaminergic Neuron Survival

ERK1 plays complex roles in PD pathogenesis[@wang2023][@cunningham2020]:

LRRK2 Interaction

The LRRK2 kinase, frequently mutated in familial PD, intersects with ERK1 signaling:

• LRRK2 can phosphorylate MAPK pathway components
• ERK1 activation may compensate for LRRK2 dysfunction
• Combined targeting shows promise in models

Therapeutic Targeting

ERK1-based therapeutic strategies in PD[@zhang2022]:

• Neuroprotective activation: Activity-based ERK1 stimulation
• Inhibition of pathogenic ERK1: Reducing toxic overactivation
• Combination approaches: ERK1 + LRRK2 or autophagy

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

In ALS, ERK1 dysregulation contributes to:

• Motor neuron vulnerability
• Glial activation
• Excitotoxicity
• Mitochondrial dysfunction

Stroke and Brain Injury

Following cerebral ischemia, ERK1 has dual roles:

• Early neuroprotective: Promotes survival signaling
• Delayed pathogenic: Contributes to excitotoxicity and inflammation

Huntington's Disease

ERK1 signaling is altered in HD:

• Mutant huntingtin affects ERK1 localization
• Dysregulated ERK1 contributes to transcriptional deficits

Interaction Network

Protein Kinase Interactions

Direct Partners:

• MEK1/2: Upstream activator
• DUSP6: Negative regulator
• RSK1/2/3: Downstream effectors
• MNK1/2: Alternative substrate

• Tau protein: Phosphorylation at disease sites
• CREB: Transcriptional activation
• Synapsin: Synaptic vesicle regulation
• PSD-95: Synaptic scaffold modification

Signaling Pathway Integration

ERK1 integrates with multiple pathways:

• PI3K/Akt: Cross-talk in survival signaling
• cAMP/PKA: Synaptic plasticity coordination
• JNK/p38: Stress response balance
• mTOR: Translational control

Therapeutic Targeting

Small Molecule Inhibitors

| Compound | Target | IC50 | Status |
|----------|--------|------|--------|
| Trametinib | MEK1/2 | 0.7 nM | Approved (cancer) |
| Selumetinib | MEK1/2 | 0.5-2.3 μM | Approved (cancer) |
| U0126 | MEK1/2 | 0.7 μM | Research |
| FR180204 | ERK1/2 | 0.5 μM | Research |

Challenges in Neurodegeneration

Emerging Approaches

• Brain-penetrant MEK inhibitors: Designed for CNS indication
• Cell-type specific activation: AAV-mediated approaches
• Combination therapy: ERK1 + disease-modifying agents

Animal Models

Genetic Models

| Model | Modification | Phenotype |
|-------|-------------|-----------|
| MAPK3 knockout | Deletion | Viable, mild cognitive deficits |
| MAPK3 conditional KO | Neuron-specific | Learning impairment |
| ERK1/2 double KO | Embryonic lethal | - |
| ERK1 knockin | Phospho-mutant | Altered plasticity |

Disease Models

• APP/PS1 + ERK1: Accelerated amyloid pathology
• MPTP + ERK1: Modulates dopaminergic toxicity
• Tau + ERK1: Enhanced tauopathy
• α-synuclein + ERK1: Altered aggregation

Biomarker Potential

ERK1 as Disease Biomarker

• Phospho-ERK1/2: Detectable in CSF and blood
• Expression changes: Correlate with disease stage
• Therapeutic monitoring: Tracks treatment response

Research Directions

• Develop sensitive detection methods
• Validate in large patient cohorts
• Establish disease-specific signatures

Cross-Links

ERK1 connects to multiple NeuroWiki pages:

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation)
• [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration)
• [Long-term Potentiation](/mechanisms/long-term-potentiation)
• [BDNF Signaling](/mechanisms/bdnf-signaling-neurodegeneration)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [MEK1/2](/proteins/mek1)
• [ERK2](/proteins/erk2)
• [CREB](/proteins/creb1-protein)
• [Tau Protein](/proteins/tau)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ERK1 (MAPK3) — Extracellular Signal-Regulated Kinase 1 discovered through SciDEX knowledge graph analysis: